Citations

Institution: Mayo Clinic Clear

Showing 10 of 108152 citations.

Predicting Epidural Hematoma Expansion in Traumatic Brain Injury: A Machine Learning Approach
Elyassirad, Danial, Gheiji, Benyamin , Vatanparast, Mahsa , Keykhosravi, Ehsan , Shafiei, Mehdi, Daneshkhah, Shirin, Fayyazi, Arya , Elyassirad, Danial , Keykhosravi, Ehsan , Hasanpour, Mohammad , Shafiei, Mehdi , Faghani, Shahriar

The Neuroradiology Journal | November 25, 2024 | Volume: 38 | Issue: 2 | Pages: 200-206

10.1177/19714009241303052 | PMID 39582207 Get It

Introduction Traumatic brain injury (TBI) is a leading cause of disability and mortality worldwide, with epidural hematoma (EDH) being a severe consequence. This study focuses on identifying factors predicting EDH volume changes in TBI patients and developing a machine learning (ML) model to predict EDH expansion. Methods The study includes patients with traumatic EDH between 2019 and 2021. Data were gathered from CT scans performed at the time of admission and 6 hours later, and subsequently analyzed. The data was divided into three cohorts: all cases, adults, and pediatrics. To predict EDH volume changes, we used Logistic Regression (LR), Random Forest (RF), XGBoost, and K-Nearest Neighbors (KNN) models. Data was divided into an 80% training set and a 20% test set. Through a rigorous process of parameter optimization and K-fold cross-validation, focusing on the area under the receiving operating curve (AUROC), we identified the best models in all cohorts. The best models were evaluated on the test sets, reporting AUROC, recall, precision, and accuracy using the youden index threshold. Results Results show that age, initial EDH volume, swirl sign, intra-hematoma air bleb, contusion, otorrhagia, subarachnoid hemorrhage, location, and other side extra-axial hematoma have significant effects on changing EDH volume. Based on test AUROC, the best models were RF for adults (82.4%), KNN for pediatrics (90%), and LR for all cases (81.6%). Discussion In this study, we identified key features for predicting EDH expansion as well as developing ML models. Using high sensitive models, can assist clinicians in identifying high-risk patients early. This allows for enhanced monitoring and timely intervention, improving patient outcomes by facilitating quicker decisions for follow-up imaging or treatment.
Stiffening symphony of aging: Biophysical changes in senescent osteocytes
Tilton, Maryam , Weivoda, Megan , Potes, Maria Astudillo , Liu, Alan Y. , Kirkland, James L. , Astudillo Potes, Maria , Gingery, Anne , Tchkonia, Tamara, Tilton, Maryam , Tchkonia, Tamar , Lu, Li‐Chun

Aging Cell | November 25, 2024 | Volume: 23 | Issue: 12 | Pages: No page available

10.1111/acel.14421 | PMID 39582140 Get It

Abstract Senescent osteocytes are key contributors to age‐related bone loss and fragility; however, the impact of mechanobiological changes in these cells remains poorly understood. This study provides a novel analysis of these changes in primary osteocytes following irradiation‐induced senescence. By integrating subcellular mechanical measurements with gene expression analyses, we identified significant, time‐dependent alterations in the mechanical properties of senescent bone cells. Increases in classical markers such as SA‐β‐Gal activity and p16 Ink4a expression levels confirmed the senescence status post‐irradiation. Our key findings include a time‐dependent increase in cytoskeletal Young's modulus and altered viscoelastic properties of the plasma membrane, affecting the contractility of primary osteocytes. Additionally, we observed a significant increase in Sclerostin ( Sost ) expression 21 days post‐irradiation. These biophysical changes may impair osteocyte mechanosensation and mechanotransduction, contributing to bone fragility. This is the first study to time‐map senescence‐associated mechanical changes in the osteocyte cytoskeleton. Our findings highlight the potential of biophysical markers as indicators of cellular senescence, providing more specificity than traditional, variable biomolecular markers. We believe these results may support biomechanical stimulation as a potential therapeutic strategy to rejuvenate aging osteocytes and enhance bone health.
Nomophobia: a challenge among healthcare professionals in Africa
Lakhani, Shan , Mbithi, Annastacia , Gandhi, Zainab , Mehta, Priyal , Kashyap, Rahul , Kashyap, Rahul , Shah, Reena , Shah, Jasmit , Singh, Aakanksha , Surani, Salim

Hospital Practice | November 25, 2024 | Volume: 53 | Issue: 1 | Pages: No page available

10.1080/21548331.2024.2432858 | PMID 39582129 Get It

Quality of life outcomes in patients participating in the CALGB 30610 trial (CALGB 70702): Alliance
Ganti, Apar Kishor , Fruth, Briant, Mix, M. , Petty, W. Jeffrey , Stinchcombe, Thomas E. , Bogart, Jeffrey A. , Dueck, Amylou C., Dueck, Amylou C. , Dueck, A. C. , Ganti, Apar K , Stinchcombe, Thomas E , Rimner, Andreas , Waqar, Saiama N , Vokes, Everett E.

Cancer | November 24, 2024 | Volume: 131 | Issue: 1 | Pages: No page available

10.1002/cncr.35663 | PMID 39580636 Get It

AbstractBackgroundCALGB 30610 trial demonstrated that once daily thoracic radiotherapy (TRT) was not superior compared to standard twice daily TRT, in patients with limited stage small cell lung cancer. Quality of life outcomes may help oncologists decide the best treatment approach.MethodsA total of 417 patients on CALGB 30610 participated in the quality‐of‐life substudy (CALGB 70702), which included the FACT Trial Outcome Index‐Lung Cancer (FACT‐L TOI), FACT‐Esophageal Cancer (FACT‐E) Eating and Swallowing Indices, ECOG Acute Esophagitis Scale, Hospital Anxiety and Depression Scale (HADS), difficulty swallowing, EQ‐5D, and treatment convenience assessment at baseline, 3, 5, 7, 12, 26, and 52 weeks after starting TRT. Primary end points included FACT‐L TOI and FACT‐E at 12 weeks. Mean changes from baseline were compared between arms using general linear mixed models.ResultsFACT‐L worsening was more in the twice daily arm at week 3 (–1.0 vs. –7.0). FACT‐L TOI worsening was less at week 3 (–2.9 vs. –7.6) and greater at week 12 (–7.6 vs. –2.8) in the once daily arm. The once daily arm had a lower EQ‐5D index worsening at 3 weeks (0.01 vs. –0.02). Increase in acute esophagitis score (1.06 vs. 2.89; p < .001) and difficulty swallowing (0.39 vs. 1.14) were greater in the twice daily arm at week 3. A total of 74.5% of patients on the once daily arm felt that treatment was convenient, compared to 67% of patients in the twice daily arm (p = .03).ConclusionsThe once daily arm had better quality‐of‐life scores earlier during treatment and was perceived to be more convenient.
Conformation-specific RNA aptamers for phenotypic distinction between normal von Willebrand factor and type 2B von Willebrand disease
Machha, Venkata R. , Moon‐Tasson, Laurie, Tange, Julie I, Santiago-Davis, Annyoceli, Pruthi, Rajiv K. , Chen, Dong , Maher, L. James , Auton, Matthew , Tischer, Alexander , Moon-Tasson, Laurie, Tange, Julie, Chen, Dong , III, Louis James Maher , Auton, Matthew , Tischer, Alexander

NAR Molecular Medicine | November 24, 2024 | Volume: 1 | Issue: 4 | Pages: No page available

10.1093/narmme/ugae021 | PMID 39719968 Get It

Abstract The A1 domain in Von Willebrand Factor (VWF) initiates coagulation through binding to platelet glycoprotein GPIbα receptors. Von Willebrand Disease (VWD)-Mutations in A1 that either impair (type 2M) or enhance (type 2B) platelet adhesion to VWF can locally destabilize and even misfold the domain. We leveraged misfolding in the gain-of-function type 2B VWD phenotype as a target, distinct from the normal conformation. Two nuclease-resistant 2′-fluoropyrimidine RNA aptamers were selected to discriminate normal A1 domains from a type 2B V1314D A1 variant in a glycosylated A1A2A3 tri-domain VWF-fragment. Two aptamers, W9 and V1, were isolated that selectively recognize, bind, and inhibit the A1–GPIbα interaction with WT A1A2A3 and V1314D A1A2A3, respectively. These aptamers were tested against their respective recombinant targets, plasma VWF, VWF concentrates, and patient plasma with the heterozygous type 2B VWD R1306W variant using clinical assays, surface plasmon resonance and inhibition assays of platelet adhesion to recombinant A1 and A1A2A3 domains under shear stress. The specificity of W9 and V1 aptamers confirms that pathological conformations of VWD Type 2B proteins are different from normal VWF. The availability of aptamers that distinguish normal plasma-derived VWF from VWD suggests potential applicability in clinical diagnosis of severe gain-of-function phenotypes.
Incretin impact on gastric function in obesity: physiology, and pharmacological, surgical and endoscopic treatments
Camilleri, Michael

The Journal of Physiology | November 24, 2024 | Volume: 603 | Issue: 24 | Pages: 7713-7729

10.1113/jp287535 | PMID 39580615 Get It

Abstract The aims of this review are to appraise the role of the stomach in satiation, the effects of incretin and other hormone agonists on weight loss and the role of altered gastric functions in their effects on obesity or glycaemic control. In addition to the gut in its role in enzymatic digestion and hormonal responses to nutrient ingestion, gastric motor functions include accommodation, trituration and emptying [gastric emptying (GE)] of food and elicitation of postprandial satiation and satiety. The postprandially released hormones most extensively studied and utilized therapeutically are glucagon‐like peptide 1 (GLP‐1) and glucose‐dependent insulinotropic peptide (GIP). Their mechanisms of action include stimulation of pancreatic β cells to produce insulin. However, GLP‐1 reduces glucagon and slows GE, whereas GIP increases glucagon and does not alter GE. Molecular modifications of GLP‐1 (which has a T 1/2 of 3 min) led to the development of long‐acting subcutaneous or oral pharmacological agents that have been approved for the treatment of obesity, and their effects on gastric function are documented. Other medications in development target other molecular mechanisms, including glucagon and amylin. Small‐molecule GLP‐1 receptor agonists are promising for the treatment of obesity and may also slow GE. Bariatric surgery and endoscopy increase satiation by restricting gastric size; in addition Roux‐en‐Y gastric bypass and to a lesser extent sleeve gastrectomy (but not endoscopic gastroplasty) increase postprandial circulating incretins, reducing appetite. In conclusion the stomach's function is integral to the impact of the most effective pharmacological and procedural reversal of obesity related to the incretin revolution. image
Calcium sensing receptor expression is downregulated in gastroenteropancreatic neuroendocrine tumours via epigenetic mechanisms
English, Katherine , Willis, Brittannie , Kooblall, Kreepa , Birla, Shweta , Shariq, Omair A. , Oberg, Ann L. , Wang, Tony, Carmichael, James, Mavrommatis, Konstantinos , Escoubet, Laure, Lines, Kate E , Goldsworthy, Michelle E. , Selberherr, Andreas , Stevenson, Mark , Thakker, Rajesh V. , Howles, Sarah

International Journal of Cancer | November 23, 2024 | Volume: 156 | Issue: 5 | Pages: 980-992

10.1002/ijc.35264 | PMID 39579056 Get It

AbstractGastroenteropancreatic neuroendocrine tumours (GEP‐NETs), which may be hormone secreting (e.g., gastrinomas and insulinomas) or non‐secreting (also known as non‐functioning NETs) are associated with severe morbidity and have a median overall survival of 75–124 months. Studies have highlighted the importance of epigenetic mechanisms in GEP‐NETs pathogenesis, with the most frequently mutated genes being the epigenetic regulators, MEN1, DAXX, and ATRX. However, the consequences of these aberrant epigenetic mechanisms are poorly understood. The calcium sensing receptor (CASR), a G protein coupled‐receptor, is epigenetically silenced in cancers, and therefore we examined its role in GEP‐NET subtypes. Using RNA‐Scope and quantitative PCR analyses in two independent tumour cohorts from Europe (n = 18 patients) and the USA (n = 46 patients) we showed that CASR mRNA is almost completely absent in gastrinomas, insulinomas and non‐functioning pancreatic NETs. Furthermore, immunohistochemical staining confirmed a significant reduction in CaSR protein expression in all GEP‐NET subtypes, compared to normal islets. DNA methylationEPIC and ATAC‐seq analyses in the pancreatic NET cell line QGP‐1 showed the CaSR promoter was both hypermethylated and in a region of closed chromatin. Furthermore, transfection of wild type CaSR into QGP‐1 cells decreased cell viability, in keeping with the CaSR having a role in cellular proliferation. In summary, our study reveals that CaSR expression is decreased in GEP‐NETs and that this reduced expression is likely due to DNA methylation and chromatin changes. Moreover, we demonstrate that transfection of the CaSR into a PNET cell line reduces cell viability, thereby indicating that the CaSR acts as a tumour suppressor in this tumour type.
LTBK-07. PROGRESSION-FREE AND OVERALL SURVIVAL RESULTS OF ECOG-ACRIN E3F05: A PHASE 3 INTERGROUP TRIAL OF RADIATION ± TEMOZOLOMIDE FOR GRADE II GLIOMAS
Schiff, David , O’Neill, Anne, Brown, Paul D. , Jenkins, Robert B. , Youssef, Emad, Uhm, Joon H. , Giglio, Pierre , Cavaliere, Robert , Ashby, Lynn S., Kleinberg, Lawrence , Schiff, David, Mehta, Minesh P. , Giannini, Caterina , Suh, John H. , Moots, Paul L

Neuro-Oncology | November 23, 2024 | Volume: 26 | Issue: Supplement_8 | Pages: viii1-viii2

10.1093/neuonc/noae165.1303 Get It

Abstract BACKGROUND Both radiation and temozolomide (TMZ) have meaningful single-modality anti-tumor activity against low-grade gliomas. ECOG-ACRIN E3F05 tested whether combined therapy with radiation and temozolomide is more effective than radiation alone in patients with grade II gliomas. METHODS Patients with grade II gliomas (central pathology review performed post hoc), no prior radiation/chemotherapy, and either age &gt; 40, uncontrolled symptoms/seizures, or progression after initial observation were randomized 1:1 to radiation 50.4 Gy alone in 28 fractions (Arm A) versus radiation 50.4 Gy with concomitant and 12 four-week cycles of post-radiation TMZ (Arm B). Randomization was stratified by 1p/19q codeletion status, age, KPS, pre-operative tumor diameter, and contrast enhancement. The primary endpoint was progression-free survival (PFS); overall survival (OS), quality of life, cognition, severe toxicities, and impact of codeletion status were secondary objectives. RESULTS The trial opened 1/09. Accrual was stopped in 1/14 after RTOG 9802 reported benefit from the addition of PCV chemotherapy to radiation in grade II gliomas. A total of 172 subjects were enrolled. Median age was 44 (range 19-78) and 54% male. 1p/19q codeletion was present in 44%. NCI CTCAE (version 4) grade 3+ toxicity was more common in participants treated with TMZ: thrombocytopenia (11%) and neutropenia (5%) versus none in the radiation alone arm. With a median follow-up of 117 months, OS was superior in Arm B (HR 0.54, 95% CI 0.31-0.95, stratified log-rank p value 0.03). OS HRs were 0.56 and 0.53 for subjects with and without 1p/19q codeleted tumors, respectively. PFS did not differ between Arms A and B (HR 0.76, 95% CI 0.44-1.28, p = 0.30). Five and ten-year OS were 78% and 70% in Arm B versus 70% and 47% in Arm A. CONCLUSION The addition of temozolomide to radiation improves overall survival in both co-deleted and non-co-deleted grade II gliomas.
Multi‐site Ultrasound‐guided Fine Needle Aspiration to Study Cells and Soluble Factors From Human Lymph Nodes
Al‐Diwani, Adam , Agrawal, Deepsha , Sheerin, Fintan , Board, Callum , Irani, Sarosh R. , Pollock, Katrina M. , Provine, Nicholas M. , Irani, Sarosh R

Current Protocols | November 23, 2024 | Volume: 4 | Issue: 11 | Pages: No page available

10.1002/cpz1.70063 | PMID 39579041 Get It

AbstractLymph nodes (LNs) are specialized secondary lymphoid tissues essential to the priming and maintenance of adaptive immune responses, including the B cell germinal center response; thus, they are central to immunity. However, the anatomically restricted and time‐resolved nature of immune priming means that sampling disease‐relevant human LNs requires specialized techniques. This article describes the application of ultrasound‐guided fine‐needle aspiration (FNA) to sample LNs, using cervical LNs of the head and neck as an exemplar. This minimally invasive technique allows collection of both immune cells and cell‐free material that are relevant to both neuroimmune diseases and basic lymphatic functions. Downstream use of cellular material can include multiplexed flow cytometry, single‐cell transcriptome sequencing (RNA‐seq), and B cell cultures. The cell‐free supernatant can be used for proteomics or other similar ‘omics approaches. This unit describes collection of samples by FNA as well as processing and storage of samples for downstream assays. © 2024 The Author(s). Current Protocols published by Wiley Periodicals LLC.Basic Protocol 1: Sampling of human cervical lymph nodes by ultrasound‐guided fine‐needle aspirationAlternate Protocol: Sampling of human lymph nodes by ultrasound‐guided fine‐needle aspiration with negative pressureBasic Protocol 2: Processing and storage of human lymph node samples
Fetal Cardiovascular Magnetic Resonance: History, Current Status, and Future Directions
Suchá, Dominika , Bohte, Anneloes E. , Leiner, Tim , Schrauben, Eric , Grotenhuis, Heynric B. , Leiner, Tim , Schrauben, Eric M , Grotenhuis, Heynric B , Suchá, Dominika , Ooij, Pim van

Journal of Magnetic Resonance Imaging | November 23, 2024 | Volume: 61 | Issue: 6 | Pages: 2357-2375

10.1002/jmri.29664 | PMID 39578988 Get It

Fetal cardiovascular magnetic resonance imaging (MRI) has emerged as a complementary modality for prenatal imaging in suspected congenital heart disease. Ongoing technical improvements extend the potential clinical value of fetal cardiovascular MRI. Ascertaining equivocal prenatal diagnostics obtained with ultrasonography allows for appropriate parental counseling and planning of postnatal surgery. This work summarizes current acquisition techniques and clinical applications of fetal cardiovascular MRI in the prenatal diagnosis and follow‐up of fetuses with congenital heart disease.Level of Evidence3Technical EfficacyStage 3